AKY-2519

N/A

Report date: 2026/05/13 20:02:10

Base Information

Drug NameAKY-2519
Drug Alias NameAKY-2519AKY-2519 (miniprotein radioconjugate targeting B7-H3)
ClassificationRadiation-emitting products > Radionuclide Drug ConjugatesBiologics > Protein drugsRadiation-emitting products > Nuclides > Actinium
Mechanisms of ActionCD276 antigen modulators
TargetsCD276 antigen
Therapy Area/IndicationsSolid tumoursProstatic Neoplasms, Castration-ResistantProstatic Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesAktis Oncology Inc
China Registration ClassN/A

Develop Information

Active CompaniesAktis Oncology Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursProstatic Neoplasms, Castration-ResistantProstatic Neoplasms +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A